多发性骨髓瘤骨髓单个核细胞CCR1和CCR5的表达及临床意义

The expression and clinic significance of CCR1 and CCR5 in patients with multiple myeloma

目的:探讨趋化因子受体CCR1和CCR5在多发性骨髓瘤(MM)患者骨髓单个核细胞(BMMNC)中的表达及临床意义。方法:半定量RT-PCR检测28例MM患者BMMNC中的CCR1和CCR5 mRNA水平。结果:46.4%患者同时表达CCR1、CCR5,17.86%患者仅表达CCR1,7.1%患者仅表达CCR5;骨质破坏>2级患者的CCR1、CCR5相对灰度值明显高于骨质破坏≤2级的患者(P<0.05);高度危险组中的CCR1、CCR5相对灰度值明显高于中、低度危险组(P<0.05),而中、低度危险组中的CCR1、CCR5相对灰度值无显著性差异(P>0.05)。结论:大部分MM患者均表达CCR1和CCR5受体,监测CCR1、CCR5两种受体在MM中BMMNC的表达可以作为评价患者骨质破坏及预后的指标。

Objective：To investigate the expression and clinic significance of ehemokine receptors CCRland CCR5 in bone marrow mononuclear cells（BMMNC） in patients with multiple myeloma. Methods： CCR1, CCR5 was quantified using reverse transcription polymerase chain reaction（RT-PCR） in BMMNC in 28 patients. Results：46.4% patients with MM had expressed CCR1 and CCRS, 17.86% patients expressed CCRI and 7. 1% patients expressed CCR5 only. The levels of CCR1 and CCR5 in patients with more than 2 sites bone destruction were much higher than those less than 2 sites bone destruction （P 〈 0. 05 ）. The levels of CCR1 and CCR5 in patients with high-risk were much higher than those with intermediate-risk have no significant difference with those patients with low-risk （ P 〉 0.05 ）. Conclusion ： Most patients with MM expressed CCR1, CCRS, the chemokine receptors CCR1, CCR5 are useful marker in the prediction of patient＇s bone destruction and out-come of postoperative.